AZD0914 Phase 1 ADME Study in Healthy Volunteers

Exclusion Criteria

• 1) Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, interfere with absorption, distribution, metabolism or excretion of drugs, or influence the results or the subject’s ability to participate in the study;
• 2) Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically significant abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QT interval corrected for heart rate (QTc) changes;
• 3) Any clinically significant abnormalities in clinical chemistry, hematology, or UA results as judged by the Investigator;
• 4) Abnormal vital signs, after 10 minutes supine rest, confirmed by repeat, defined as any of the following: systolic blood pressure <90 mmHg or >140 mmHg; diastolic blood pressure <50 mmHg or >90 mmHg; or heart rate <40 or >100 beats per minute;
• 5) Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IP;